Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer

BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dys...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2021-04, Vol.73 (4), p.1399-1418
Hauptverfasser: Ostroumov, Dmitrij, Duong, Steven, Wingerath, Jessica, Woller, Norman, Manns, Michael P., Timrott, Kai, Kleine, Moritz, Ramackers, Wolf, Roessler, Stephanie, Nahnsen, Sven, immunoglobulin and immunoreceptor tyrosiCzemmel, Dittrich‐Breiholz, Oliver, Eggert, Tobias, Kühnel, Florian, Wirth, Thomas C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1418
container_issue 4
container_start_page 1399
container_title Hepatology (Baltimore, Md.)
container_volume 73
creator Ostroumov, Dmitrij
Duong, Steven
Wingerath, Jessica
Woller, Norman
Manns, Michael P.
Timrott, Kai
Kleine, Moritz
Ramackers, Wolf
Roessler, Stephanie
Nahnsen, Sven
immunoglobulin and immunoreceptor tyrosiCzemmel
Dittrich‐Breiholz, Oliver
Eggert, Tobias
Kühnel, Florian
Wirth, Thomas C.
description BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive. APPROACH AND RESULTS We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells. CONCLUSIONS Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.
doi_str_mv 10.1002/hep.31466
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2427524010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512167671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</originalsourceid><addsrcrecordid>eNp1kMGO0zAQhi0EYkvhwAsgS1zgkHbGiZ3kiKrubqUieggnDpbrjFmXNCl2A-xtH4Fn5EnWSwsHJE5zmE-ffn2MvUSYIYCY39BhlmOh1CM2QSnKLM8lPGYTECVkNeb1BXsW4w4A6kJUT9lFLkpUUtYT9qkJpo82-MNx2BPfhMH5zvef-aql_uidp8ib1dWq4SZyw9-b8IUCHxxvft39XFDX8eWPGzPGox967nu-9t_Sf2F6S-E5e-JMF-nF-U7Zx8tls7jO1h-uVot368ymNSrb5ijLAl1RkCGzJQuuaqFCKhW2zhgnCaFSylSEQlZg8lpa21qLldwCuHzK3py8hzB8HSke9d5Hm7aZnoYxalGIUooCEBL6-h90N4yhT-u0kChQlarERL09UTYMMQZy-hD83oRbjaAfiutUXP8unthXZ-O43VP7l_yTOAHzE_Ddd3T7f5O-Xm5Oynt2JInU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512167671</pqid></control><display><type>article</type><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</creator><creatorcontrib>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</creatorcontrib><description>BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive. APPROACH AND RESULTS We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells. CONCLUSIONS Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.31466</identifier><identifier>PMID: 32716559</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Aged ; Animal models ; Animals ; Apoptosis ; Bile Duct Neoplasms - genetics ; Bile Duct Neoplasms - immunology ; Bile Duct Neoplasms - pathology ; Biomarkers, Tumor - genetics ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - pathology ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; Cell differentiation ; Cell Line, Tumor ; Cholangiocarcinoma ; Cholangiocarcinoma - genetics ; Cholangiocarcinoma - immunology ; Cholangiocarcinoma - pathology ; Disease Models, Animal ; Drug Therapy, Combination ; Female ; Gene expression ; Gene Expression Profiling - methods ; Hepatocellular carcinoma ; Hepatocytes ; Hepatology ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Liver cancer ; Liver diseases ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - immunology ; Liver Neoplasms - pathology ; Lymphocytes ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; PD-1 protein ; Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors ; Receptors, Immunologic - antagonists &amp; inhibitors ; Receptors, Immunologic - genetics ; Transcriptome ; Transcriptomes ; Treatment Outcome ; Tumor Burden - drug effects ; Tyrosine</subject><ispartof>Hepatology (Baltimore, Md.), 2021-04, Vol.73 (4), p.1399-1418</ispartof><rights>2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</citedby><cites>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.31466$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.31466$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32716559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ostroumov, Dmitrij</creatorcontrib><creatorcontrib>Duong, Steven</creatorcontrib><creatorcontrib>Wingerath, Jessica</creatorcontrib><creatorcontrib>Woller, Norman</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Timrott, Kai</creatorcontrib><creatorcontrib>Kleine, Moritz</creatorcontrib><creatorcontrib>Ramackers, Wolf</creatorcontrib><creatorcontrib>Roessler, Stephanie</creatorcontrib><creatorcontrib>Nahnsen, Sven</creatorcontrib><creatorcontrib>immunoglobulin and immunoreceptor tyrosiCzemmel</creatorcontrib><creatorcontrib>Dittrich‐Breiholz, Oliver</creatorcontrib><creatorcontrib>Eggert, Tobias</creatorcontrib><creatorcontrib>Kühnel, Florian</creatorcontrib><creatorcontrib>Wirth, Thomas C.</creatorcontrib><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive. APPROACH AND RESULTS We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells. CONCLUSIONS Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</description><subject>Aged</subject><subject>Animal models</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Bile Duct Neoplasms - genetics</subject><subject>Bile Duct Neoplasms - immunology</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell differentiation</subject><subject>Cell Line, Tumor</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - genetics</subject><subject>Cholangiocarcinoma - immunology</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling - methods</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatocytes</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Middle Aged</subject><subject>PD-1 protein</subject><subject>Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors</subject><subject>Receptors, Immunologic - antagonists &amp; inhibitors</subject><subject>Receptors, Immunologic - genetics</subject><subject>Transcriptome</subject><subject>Transcriptomes</subject><subject>Treatment Outcome</subject><subject>Tumor Burden - drug effects</subject><subject>Tyrosine</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMGO0zAQhi0EYkvhwAsgS1zgkHbGiZ3kiKrubqUieggnDpbrjFmXNCl2A-xtH4Fn5EnWSwsHJE5zmE-ffn2MvUSYIYCY39BhlmOh1CM2QSnKLM8lPGYTECVkNeb1BXsW4w4A6kJUT9lFLkpUUtYT9qkJpo82-MNx2BPfhMH5zvef-aql_uidp8ib1dWq4SZyw9-b8IUCHxxvft39XFDX8eWPGzPGox967nu-9t_Sf2F6S-E5e-JMF-nF-U7Zx8tls7jO1h-uVot368ymNSrb5ijLAl1RkCGzJQuuaqFCKhW2zhgnCaFSylSEQlZg8lpa21qLldwCuHzK3py8hzB8HSke9d5Hm7aZnoYxalGIUooCEBL6-h90N4yhT-u0kChQlarERL09UTYMMQZy-hD83oRbjaAfiutUXP8unthXZ-O43VP7l_yTOAHzE_Ddd3T7f5O-Xm5Oynt2JInU</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Ostroumov, Dmitrij</creator><creator>Duong, Steven</creator><creator>Wingerath, Jessica</creator><creator>Woller, Norman</creator><creator>Manns, Michael P.</creator><creator>Timrott, Kai</creator><creator>Kleine, Moritz</creator><creator>Ramackers, Wolf</creator><creator>Roessler, Stephanie</creator><creator>Nahnsen, Sven</creator><creator>immunoglobulin and immunoreceptor tyrosiCzemmel</creator><creator>Dittrich‐Breiholz, Oliver</creator><creator>Eggert, Tobias</creator><creator>Kühnel, Florian</creator><creator>Wirth, Thomas C.</creator><general>Wolters Kluwer Health, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><author>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Animal models</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Bile Duct Neoplasms - genetics</topic><topic>Bile Duct Neoplasms - immunology</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell differentiation</topic><topic>Cell Line, Tumor</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - genetics</topic><topic>Cholangiocarcinoma - immunology</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling - methods</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatocytes</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Middle Aged</topic><topic>PD-1 protein</topic><topic>Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors</topic><topic>Receptors, Immunologic - antagonists &amp; inhibitors</topic><topic>Receptors, Immunologic - genetics</topic><topic>Transcriptome</topic><topic>Transcriptomes</topic><topic>Treatment Outcome</topic><topic>Tumor Burden - drug effects</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ostroumov, Dmitrij</creatorcontrib><creatorcontrib>Duong, Steven</creatorcontrib><creatorcontrib>Wingerath, Jessica</creatorcontrib><creatorcontrib>Woller, Norman</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Timrott, Kai</creatorcontrib><creatorcontrib>Kleine, Moritz</creatorcontrib><creatorcontrib>Ramackers, Wolf</creatorcontrib><creatorcontrib>Roessler, Stephanie</creatorcontrib><creatorcontrib>Nahnsen, Sven</creatorcontrib><creatorcontrib>immunoglobulin and immunoreceptor tyrosiCzemmel</creatorcontrib><creatorcontrib>Dittrich‐Breiholz, Oliver</creatorcontrib><creatorcontrib>Eggert, Tobias</creatorcontrib><creatorcontrib>Kühnel, Florian</creatorcontrib><creatorcontrib>Wirth, Thomas C.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ostroumov, Dmitrij</au><au>Duong, Steven</au><au>Wingerath, Jessica</au><au>Woller, Norman</au><au>Manns, Michael P.</au><au>Timrott, Kai</au><au>Kleine, Moritz</au><au>Ramackers, Wolf</au><au>Roessler, Stephanie</au><au>Nahnsen, Sven</au><au>immunoglobulin and immunoreceptor tyrosiCzemmel</au><au>Dittrich‐Breiholz, Oliver</au><au>Eggert, Tobias</au><au>Kühnel, Florian</au><au>Wirth, Thomas C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2021-04</date><risdate>2021</risdate><volume>73</volume><issue>4</issue><spage>1399</spage><epage>1418</epage><pages>1399-1418</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><abstract>BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive. APPROACH AND RESULTS We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells. CONCLUSIONS Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>32716559</pmid><doi>10.1002/hep.31466</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2021-04, Vol.73 (4), p.1399-1418
issn 0270-9139
1527-3350
language eng
recordid cdi_proquest_miscellaneous_2427524010
source MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals
subjects Aged
Animal models
Animals
Apoptosis
Bile Duct Neoplasms - genetics
Bile Duct Neoplasms - immunology
Bile Duct Neoplasms - pathology
Biomarkers, Tumor - genetics
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - immunology
Carcinoma, Hepatocellular - pathology
CD8 antigen
CD8-Positive T-Lymphocytes - immunology
Cell differentiation
Cell Line, Tumor
Cholangiocarcinoma
Cholangiocarcinoma - genetics
Cholangiocarcinoma - immunology
Cholangiocarcinoma - pathology
Disease Models, Animal
Drug Therapy, Combination
Female
Gene expression
Gene Expression Profiling - methods
Hepatocellular carcinoma
Hepatocytes
Hepatology
Humans
Immune Checkpoint Inhibitors - therapeutic use
Liver cancer
Liver diseases
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - immunology
Liver Neoplasms - pathology
Lymphocytes
Lymphocytes T
Lymphocytes, Tumor-Infiltrating - immunology
Male
Mice
Mice, Inbred C57BL
Middle Aged
PD-1 protein
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Receptors, Immunologic - antagonists & inhibitors
Receptors, Immunologic - genetics
Transcriptome
Transcriptomes
Treatment Outcome
Tumor Burden - drug effects
Tyrosine
title Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A59%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcriptome%20Profiling%20Identifies%20TIGIT%20as%20a%20Marker%20of%20T%E2%80%90Cell%20Exhaustion%20in%20Liver%20Cancer&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Ostroumov,%20Dmitrij&rft.date=2021-04&rft.volume=73&rft.issue=4&rft.spage=1399&rft.epage=1418&rft.pages=1399-1418&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.31466&rft_dat=%3Cproquest_cross%3E2512167671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512167671&rft_id=info:pmid/32716559&rfr_iscdi=true